Tipranavir (Aptivus®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000458
English
Authors' recommendations:
Tipranavir (Aptivus®) should be recommended for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection, only for the treatment of highly pre-treated adult patients who have failed multiple protease inhibitors (PI), and where resistance profiling suggests it is appropriate.
Use should be in accordance with the British HIV Association (BHIVA) guidance.
Tipranavir (Aptivus®) is not presently recommended for shared care.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=85965&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- HIV Protease Inhibitors
- HIV Infections
- Anti-HIV Agents
- Pyridines
- Pyrones
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.